Molecular Hydrogen for Rheumatoid Arthritis
Molecular hydrogen (H₂) is a therapeutic medical gas that has attracted scientific interest for its potential role in inflammatory diseases, including rheumatoid arthritis (RA). Since the landmark 2007 discovery that H₂ can selectively scavenge hydroxyl radicals, nearly 2,000 research papers have been published globally, with over 300 original articles reporting therapeutic effects across more than 160 disease models[^c1]. In the context of RA, molecular hydrogen has been investigated for its antioxidant, anti-inflammatory, and immunomodulatory properties, targeting the oxidative stress-driven inflammatory feedback loops that characterize the disease[^c2].
Clinical evidence includes an open-label pilot study in which 20 RA patients who consumed hydrogen-rich water showed significant reductions in disease activity scores and oxidative stress markers[^c3], followed by a randomized, double-blind, placebo-controlled trial of intravenous hydrogen-saline infusions in 24 patients that confirmed significant DAS28 reductions and decreased levels of interleukin-6 and matrix metalloproteinase-3[^c4]. Additional studies have explored hydrogen's effects on immune cell populations, demonstrating modulation of multiple T cell and B cell subsets[^c5]. Newer delivery approaches, including oral solid hydrogen capsules for sustained release and nanomaterial-based systems for localized hydrogen generation at arthritic joints, have expanded the potential applications of hydrogen therapy for RA.
No clinical study of hydrogen therapy for RA has assessed radiographic progression of structural joint damage using measures such as the Sharp or Larsen scores. The 2012 open-label pilot was only 12 weeks in duration—too short to evaluate joint erosion—and no imaging was performed[^c3]. The 2014 intravenous hydrogen-saline trial reported a reduction in matrix metalloproteinase-3, a biomarker associated with cartilage degradation, but did not include radiographic assessment[^c4]. This represents a significant gap in the evidence base for hydrogen therapy as a disease-modifying intervention in RA.
Despite encouraging findings, the evidence base remains preliminary. A 2026 systematic review concluded that while hydrogen may serve as a promising adjunctive therapy, the absence of large-scale standardized trials makes incorporation into routine clinical practice premature[^c6]. The literature for most disease models consists of only a small number of studies with heterogeneous protocols[^c7].